Watson introduces Amethia Lo and ethinyl estradiol tablets

Download PDF Copy

Dec 8 2011

NewsGuard 100/100 Score

Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that under a settlement with Teva Women's Health, Watson has launched Amethia® Lo (levonorgestrel/ethinyl estradiol (0.1mg/0.02mg) and ethinyl estradiol (0.01mg)) tablets, the generic equivalent of Teva Women's Health, Inc.'s LoSEASONIQUE®. Amethia® Lo tablets are indicated for the prevention of pregnancy.

As a "first applicant" to submit a substantially complete ANDA, Watson is eligible for 180 days of shared generic market exclusivity. For the most recent twelve months ending September 30, 2011, LoSEASONIQUE® had sales of approximately $28 million, according to IMS Health data.

Source:

Watson Pharmaceuticals, Inc.

Posted in: Women's Health News | Pharmaceutical News

Tags: Estradiol, Levonorgestrel, Medicaid, Medicare, Pharmaceuticals, Pregnancy, Urology, Women's Health

Comments (0)

Download PDF Copy

Suggested Reading

How nutrition and telomere dynamics shape beauty and aging in women

How nutrition and telomere dynamics shape beauty and aging in women

Early RSV vaccination in pregnancy provides best protection for newborns

Early RSV vaccination in pregnancy provides best protection for newborns

Healthy lifestyle choices can offset genetic risk for brain diseases

Healthy lifestyle choices can offset genetic risk for brain diseases

Tiny molecule offers hope in reducing opioid side effects

Tiny molecule offers hope in reducing opioid side effects

Research reveals only a few brain regions remain untouched by transition to motherhood

Research reveals only a few brain regions remain untouched by transition to motherhood

Study focuses on COPD progression in younger populations

Study focuses on COPD progression in younger populations

Vitamin B12 boosts testosterone levels in men with infertility

Vitamin B12 boosts testosterone levels in men with infertility

Combination therapy shows promising results in treating stage 3 melanoma

Combination therapy shows promising results in treating stage 3 melanoma

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care